The independent medical news service

Men with a high genetic risk for developing prostate cancer may be able to offset the risk for lethal disease by maintaining a healthy lifestyle, findings indicate.

Combination therapy with nivolumab and ipilimumab has shown antitumor activity in a phase 2 study of men with metastatic castration-resistant prostate cancer and a positive immunogenic signature.

Researchers have identified an association between socioeconomic deprivation and poor survival in people with cancer participating in clinical trials.

One ultra-high dose of radiation may offer similar benefits and risks to those of an extreme hypofractionated stereotactic body radiotherapy regimen for men with organ-confined prostate cancer, indicate the results of a phase 2 proof-of-concept trial.

The number and location of bone metastases, as determined by conventional imaging, are associated with the survival benefit of prostate radiotherapy in men with newly diagnosed metastatic prostate cancer, STAMPEDE trial data show.

The clinical cell-cycle risk score is able to accurately predict metastasis risk in men undergoing dose-escalated radiation therapy, with or without androgen deprivation therapy, for intermediate- to high-risk localized prostate cancer, research suggests.

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.

A large study has failed to find an association between receipt of androgen deprivation therapy and a reduced risk for SARS-CoV-2 infection.

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer derive a significant radiographic progression-free survival benefit from the addition of apalutamide to abiraterone acetate, suggest phase 3 trial data.

The decrease in PSA screening in recent years may have come at the cost of increased levels of later-stage disease at prostate cancer diagnosis, suggests research presented at the 2021 Genitourinary Cancers Symposium.

Abiraterone acetate or apalutamide given in combination with androgen deprivation therapy offer the best survival outcomes for patients with metastatic castration-sensitive prostate cancer, a network meta-analysis shows.

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

Patients with intermediate-to-high-risk localized prostate cancer report similar long-term bowel and urinary symptoms and sexual function whether treated with ultra-hypofractionated radiotherapy or conventional radiotherapy, phase 3 study data show.

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

US researchers report that men with clinically localized, high-risk prostate cancer are no more likely to experience adverse pathologic outcomes if radical prostatectomy is delayed for up to 6 months rather than occurring within 31–60 days of diagnosis.